Tricida's Future In Doubt After Renal Outcomes Failure In CKD With Metabolic Acidosis
Executive Summary
The company's hopes to bring veverimer to market to slow chronic kidney disease progression in patients with metabolic acidosis appear to be dashed.
You may also be interested in...
Finance Watch: PTC Secures Up To $1bn In Funding From Blackstone
Public Company Edition: PTC will get $350m up front as part of an initial $500m commitment. Also, while Biohaven and Vaxcyte launched traditional follow-on offerings, Recursion and Agios took the private placement and royalty sale routes, while others revealed job cuts and other strategic updates.
Keeping Track: US FDA Has Clinical Questions For Tricida, Gilead And BioMarin; Enspryng And Winlevi Approved
The latest drug approval and decision news from the Pink Sheet’s US FDA Performance Tracker.
Blueprint’s Evolution On Its Path To Financial Sustainability
Chief operating officer Christina Rossi talked to Scrip about the company’s new blockbuster-sized commercial opportunity for Ayvakit and the company’s next phase: financial sustainability.